# International Journal of Engineering Research and Science & Technology

IJERST

www.ijerst.org

ISSN : 2319-5991

Vol. 22 No. 1 (2026)



ijerst.editor@gmail.com

editor@ijerst.com

International Journal of Engineering Research and Science & Technology

ISSN 2319-5991 www.ijerst.com
Vol. 22, No. 1, 2026

Peer Reviewed, Referred & Indexed Journal

**Research Paper**

# NOVEL DRUG DELIVERY SYSTEMS FOR CERVICAL CANCER: A COMPREHENSIVE REVIEW

Vigyan Singh[1]* , Balbir Singh[2] , Vaibhav Srivastava[3]

[*1] **Smt. Vidyawati College of Pharmacy, Jhansi,( U.P.) India**

[2] **Institute of Biomedical Sciences,**

**Bundelkhand University, Jhansi,( U.P.) India**

[3]**Smt. Vidyawati College of Pharmacy, Jhansi,( U.P.) India**

*Corresponding Author E-mail: vigyan.s2000@gmail.com

**Abstract**

Cervical cancer remains a major public health concern worldwide, particularly in developing countries. Conventional chemotherapy and radiotherapy are associated with systemic toxicity, poor bioavailability, and non-specific targeting. Novel Drug Delivery Systems (NDDS) have emerged as promising strategies to improve therapeutic efficacy, reduce side effects, and enhance patient compliance. This review highlights recent advances in novel drug delivery approaches for cervical cancer, including nanoparticles, liposomes, polymeric micelles, dendrimers, nanoemulsions, and targeted delivery systems.

**Keywords:** Cervical cancer, Novel drug delivery system, Nanoparticles, Targeted therapy, Controlled release

Received: 08-01-2026 Accepted: 16-02-2026 Published: 23-02-2026

## 1. Introduction

Cervical cancer is one of the most common malignancies affecting women globally. Human papillomavirus (HPV) infection is the primary etiological factor. Although early-stage cervical cancer can be treated effectively, advanced stages require chemotherapy and radiotherapy, which often result in severe adverse effects. Novel drug delivery systems aim to overcome the limitations of conventional therapy by enhancing drug solubility, stability, targeting ability, and controlled release.

## 2. Limitations of Conventional Drug Delivery in Cervical Cancer

- Non-specific distribution of anticancer drugs
- High systemic toxicity
- Low therapeutic index
- Poor patient compliance
- Drug resistance

These challenges necessitate the development of advanced drug delivery systems.

## 3. Novel Drug Delivery Systems for Cervical Cancer

**Table 1. Summary of Novel Drug Delivery Systems for Cervical Cancer (2020–2025)**

| Drug Delivery System | Carrier Material | Drug/Agent | Targeting Strategy | Key Outcome | Recent Reference |
|---|---|---|---|---|---|
| Nanoparticles | PLGA, chitosan | Paclitaxel | Passive (EPR) | Enhanced tumor accumulation | Peer et al., 2020 |
| Solid Lipid | Glyceryl | Doxorubicin | Passive | Reduced systemic | Tiwary et |

| | | | | | |
|---|---|---|---|---|---|
| Nanoparticles | monostearate | | | toxicity | al., 2025 |
| Liposomes | Phospholipids | Cisplatin | Passive/Active | Improved safety profile | Torchilin, 2021 |
| Polymeric micelles | PEG-PLA | Docetaxel | Passive | Increased bioavailability | Jain & Mishra, 2022 |
| ADCs | Monoclonal antibody | MMAE | Active (Tissue factor) | Clinical efficacy | Zhang et al., 2024 |

**4. Recent Advances and Clinical Perspectives**

Recent advances between **2020 and 2025** indicate a significant paradigm shift in cervical cancer management toward **precision-guided, localized, and molecularly targeted drug delivery strategies**. Conventional chemotherapy for cervical cancer is often limited by poor tumor selectivity, systemic toxicity, and the development of multidrug resistance. To overcome these challenges, novel drug delivery systems have been extensively explored to enhance therapeutic efficacy while minimizing adverse effects.

Among these, **nanocarrier-based delivery systems** have emerged as a promising approach. **Solid lipid nanoparticles (SLNs)** offer advantages such as high drug loading capacity, controlled drug release, excellent biocompatibility, and improved stability. SLNs have demonstrated enhanced cellular uptake and prolonged circulation time, leading to improved antitumor activity in cervical cancer models. Similarly, **polymeric nanoparticles**, particularly those based on biodegradable polymers such as PLGA, chitosan, and PEGylated systems, have shown superior pharmacokinetic profiles, improved bioavailability, and reduced off-target toxicity. **Lipid–polymer hybrid nanoparticles** further combine the structural stability of polymeric cores with the biomimetic properties of lipid shells, resulting in enhanced tumor accumulation and controlled drug release.

A major clinical breakthrough in targeted therapy has been the development of **antibody–drug conjugates (ADCs)**. ADCs enable the selective delivery of highly potent cytotoxic agents directly to cancer cells by exploiting tumor-specific antigens. In cervical cancer, **tissue factor (TF)-targeted ADCs** have gained significant clinical attention due to their high expression on cervical cancer cells and limited expression in normal tissues. These ADCs have demonstrated remarkable clinical efficacy, improved response rates, and manageable safety profiles, marking a new milestone in cervical cancer therapeutics.

Another rapidly evolving area is **stimuli-responsive drug delivery systems**, which enable site-specific and controlled drug release within the tumor microenvironment. **pH-responsive systems** exploit the acidic nature of the tumor environment to trigger drug release selectively at the tumor site. **Enzyme-responsive carriers** respond to overexpressed enzymes such as matrix metalloproteinases, ensuring localized activation of the therapeutic agent. **Redox-responsive systems**, designed to respond to elevated intracellular glutathione levels, facilitate intracellular drug release, while **temperature-responsive systems** offer controlled release in response to localized hyperthermia. These smart delivery systems significantly enhance therapeutic precision and reduce systemic exposure.

Recent studies have also emphasized **localized intravaginal drug delivery platforms** as a highly effective strategy for cervical cancer treatment. Delivery systems such as **nanofibers, hydrogels, vaginal films, and in situ gelling systems** provide sustained and controlled drug release directly at the site of action. These platforms enhance drug retention time, improve

patient compliance, and significantly reduce systemic side effects. Intravaginal nanocarrier-based formulations have shown promising results in achieving high local drug concentrations while minimizing plasma drug levels.

Furthermore, **combination therapy approaches** have gained momentum in recent years. The integration of **chemotherapy with immunotherapy, gene therapy, or photothermal therapy using nanocarriers** has demonstrated synergistic therapeutic effects. Nanocarriers facilitate the co-delivery of multiple therapeutic agents, enabling enhanced immune activation, gene silencing of oncogenic pathways, and reversal of drug resistance mechanisms. These combination strategies have shown improved tumor regression, reduced recurrence rates, and enhanced survival outcomes in preclinical and early clinical studies.

From a clinical perspective, several of these advanced delivery systems have progressed into **clinical trials**, highlighting their translational potential. However, challenges such as large-scale manufacturing, long-term safety, regulatory approval, and cost-effectiveness remain to be addressed. Despite these hurdles, the integration of nanotechnology, molecular targeting, and localized delivery systems represents a transformative advancement in cervical cancer therapy.

Overall, recent innovations underscore a clear movement toward **personalized, targeted, and minimally invasive treatment modalities**, offering new hope for improved therapeutic outcomes and quality of life in patients with cervical cancer.

## 5. Extended Results and Discussion

The present analysis highlights the substantial progress achieved in cervical cancer drug delivery systems over recent years, particularly with the integration of nanotechnology and targeted therapeutic approaches. The results from preclinical and emerging clinical studies consistently demonstrate that advanced delivery platforms significantly outperform conventional formulations in terms of efficacy, safety, and patient compliance.

### Nanocarrier-Based Therapeutic Outcomes

Experimental results indicate that **nanocarrier-mediated drug delivery** markedly enhances drug accumulation at the tumor site. Solid lipid nanoparticles (SLNs) and polymeric nanoparticles exhibited prolonged circulation time and improved cellular uptake, leading to enhanced cytotoxic effects against cervical cancer cell lines. The observed increase in antitumor efficacy can be attributed to improved pharmacokinetics and the enhanced permeability and retention (EPR) effect, which facilitates passive targeting of nanocarriers within tumor tissues. In comparison to free drug formulations, nanoparticle-based systems demonstrated a significant reduction in systemic toxicity, as evidenced by lower off-target organ damage in preclinical models (figure1).


Figure 1: Classification of novel drug delivery systems for cervical cancer.

### Targeted Delivery and Antibody–Drug Conjugates

The results further emphasize the importance of **active targeting strategies**, particularly antibody–drug conjugates (ADCs). Tissue factor (TF)-targeted ADCs showed superior selectivity toward cervical cancer cells, resulting in higher intracellular drug concentrations and enhanced apoptosis induction. Clinical observations reveal improved response rates and manageable adverse effects, suggesting that ADC-based therapies represent a clinically viable alternative to traditional chemotherapy. The selectivity

achieved through receptor-mediated targeting reduces collateral damage to healthy tissues, thereby improving the therapeutic index (figure 2).




Figure 2: Mechanism of targeted and stimuli-responsive drug delivery to cervical cancer cells rapd cells.

**Performance of Stimuli-Responsive Systems**

Stimuli-responsive drug delivery systems demonstrated precise control over drug release profiles. pH-responsive and enzyme-sensitive nanocarriers released their payload preferentially in the tumor microenvironment, confirming the effectiveness of microenvironment-triggered drug activation. Redox-responsive systems showed efficient intracellular drug release due to elevated glutathione levels in cancer cells, enhancing cytotoxic efficacy. These results support the hypothesis that smart delivery systems can overcome limitations associated with premature drug release and poor tumor specificity.

**Localized Intravaginal Delivery Platforms**

Results from localized intravaginal delivery systems revealed significant improvements in local drug concentration and sustained therapeutic effects. Nanofibers, hydrogels, and in situ gelling systems maintained prolonged residence time at the cervical site, resulting in enhanced drug bioavailability and reduced dosing frequency. Comparative studies demonstrated that localized delivery minimized systemic exposure, thereby reducing adverse effects commonly associated with systemic chemotherapy. These findings underscore the clinical relevance of intravaginal delivery as a patient-friendly and effective approach for cervical cancer management(figure 3).




Figure 3: Localized versus systemic drug delivery routes for cervical cancer.

**Combination Therapy and Resistance Modulation**

The co-delivery of chemotherapeutic agents with immunomodulators or gene therapy components via nanocarriers yielded synergistic therapeutic outcomes. Results showed enhanced immune activation, downregulation of oncogenic pathways, and reversal of multidrug resistance mechanisms. The ability of nanocarriers to co-encapsulate multiple agents enabled controlled and synchronized release, leading to improved tumor suppression and reduced recurrence rates. These findings suggest that combination therapy using advanced delivery systems may offer a powerful strategy against treatment-resistant cervical cancer.

**Clinical Implications and Translational Challenges**

From a clinical perspective, the discussed results highlight the translational potential of advanced drug delivery systems. Several nanocarrier-based formulations and ADCs have progressed into clinical evaluation, demonstrating promising efficacy and safety profiles. However, challenges related to scalability, regulatory approval, long-term toxicity, and cost-effectiveness remain significant barriers to widespread clinical adoption. Addressing these limitations will be crucial for successful translation from bench to bedside.

**Overall Discussion**

Collectively, the extended results and discussion reinforce the growing consensus that advanced drug delivery systems represent a transformative

approach in cervical cancer therapy. The convergence of nanotechnology, targeted delivery, and localized treatment platforms offers improved therapeutic outcomes with reduced systemic toxicity. These advancements pave the way toward personalized and precision-based treatment strategies, with the potential to significantly enhance patient survival and quality of life.

**Table 2. Comparison of Conventional vs Novel Drug Delivery Systems**

| | **Conventional Therapy** | **Novel Drug Delivery Systems** |
|---|---|---|
| Target specificity | Low | High |
| Systemic toxicity | High | Reduced |
| Drug bioavailability | Low | Improved |
| Controlled release | Absent | Present |
| Patient compliance | Moderate | High |

Recent literature (2020–2025) consistently reports that nano-enabled drug delivery systems outperform conventional dosage forms in terms of therapeutic index and safety profile. Solid lipid nanoparticles and polymeric micelles have demonstrated enhanced cellular uptake in HeLa and SiHa cervical cancer cell lines, leading to increased apoptosis and reduced tumor volume in animal models. Liposomal formulations of paclitaxel and cisplatin significantly reduced nephrotoxicity and neurotoxicity compared to free drugs.

Antibody–drug conjugates, such as tissue-factor-targeted ADCs, have shown notable clinical efficacy in recurrent and metastatic cervical cancer, highlighting the translational potential of targeted delivery systems. Localized delivery systems, including intravaginal inserts and hydrogels, achieved prolonged drug residence time at the tumor site, minimizing systemic circulation and adverse effects.

Comparative analyses reveal that while nanoparticles and liposomes provide superior targeting and controlled release, challenges remain related to large-scale manufacturing, long-term stability, and regulatory approval. Overall, recent studies confirm that novel drug delivery systems significantly enhance treatment efficacy, reduce toxicity, and improve patient compliance, supporting their future integration into clinical practice.

## 5. Challenges and Future Prospects

One of the major challenges associated with nanocarrier-based drug delivery systems is **large-scale manufacturing**. Laboratory-scale preparation methods often lack reproducibility when translated to industrial production. Maintaining batch-to-batch consistency in particle size, drug loading, surface characteristics, and release profiles is technically demanding. Variations in these parameters can significantly affect pharmacokinetics, therapeutic efficacy, and safety. Furthermore, scaling up advanced systems such as antibody–drug conjugates and stimuli-responsive nanoparticles requires sophisticated infrastructure and stringent quality control measures, which increase production complexity and cost.

### Regulatory and Approval Barriers

The **regulatory approval process** for advanced delivery systems presents another significant hurdle. Nanomedicines and targeted delivery platforms often do not fit neatly into existing regulatory frameworks, as they combine features of drugs, biologics, and medical devices. Comprehensive evaluation of long-term toxicity, immunogenicity, biodistribution, and metabolic fate is required before regulatory approval can be granted. The lack of standardized guidelines for the assessment of nanocarriers further complicates the approval process, leading to

extended timelines and increased development costs.

**Stability and Storage-Related Challenges**

**Stability issues** remain a critical concern, particularly for lipid-based and polymeric nanocarriers. Physical instability, such as aggregation, drug leakage, or changes in particle size during storage, can compromise product quality and therapeutic performance. Chemical instability, including drug degradation and polymer oxidation, further limits shelf life. For antibody–drug conjugates, maintaining linker stability while ensuring efficient intracellular drug release is a delicate balance. Addressing these stability challenges is essential to ensure safe storage, transportation, and clinical use.

**Economic and Cost-Effectiveness Concerns**

The **high cost of development and production** poses a significant barrier to the adoption of advanced drug delivery systems, especially in low- and middle-income countries where the burden of cervical cancer is highest. Complex synthesis processes, expensive raw materials, and the need for specialized manufacturing facilities contribute to elevated costs. Without cost-effective production strategies, equitable access to these advanced therapies remains limited, potentially widening global healthcare disparities.

**Future Prospects and Research Directions**

Despite these challenges, the future of advanced cervical cancer therapy remains highly promising. **Clinical translation** should be prioritized through well-designed, large-scale clinical trials to establish long-term safety and therapeutic benefits. Greater collaboration between academic researchers, clinicians, industry stakeholders, and regulatory agencies will be essential to streamline development pathways and accelerate approval processes.

Emerging trends in **personalized medicine** are expected to play a transformative role in future therapeutic strategies. The integration of molecular profiling, biomarker identification, and patient-specific tumor characteristics can enable the design of customized drug delivery systems with enhanced efficacy and minimal toxicity. Personalized nanomedicine approaches may optimize drug selection, dosing, and delivery routes based on individual patient needs.

**Integration of Emerging Technologies**

Future research is also likely to focus on the integration of **artificial intelligence, machine learning, and advanced imaging techniques** to optimize formulation design, predict therapeutic responses, and monitor treatment outcomes. Smart delivery systems capable of real-time response to tumor microenvironment changes represent a next-generation approach to cancer therapy. Additionally, the development of biodegradable, environmentally sustainable, and patient-friendly delivery platforms will further enhance clinical acceptance.

**Outlook and Conclusion**

In conclusion, while challenges related to manufacturing, regulation, stability, and cost remain significant, continuous technological advancements and interdisciplinary collaboration offer strong prospects for overcoming these limitations. The future direction of cervical cancer treatment lies in the successful translation of advanced, targeted, and personalized drug delivery systems into clinical practice. These innovations hold the potential to revolutionize therapeutic outcomes, reduce treatment-related toxicity, and improve the overall quality of life for patients worldwide.

## 6. Conclusion

Novel drug delivery systems represent a transformative approach in the management of cervical cancer. Evidence from recent studies (2020–2025) confirms that nanocarriers, antibody–drug conjugates, and localized delivery platforms significantly improve drug targeting, therapeutic efficacy, and safety compared to conventional chemotherapy. Among these, targeted nanocarriers and ADCs

demonstrate strong translational and clinical potential, while intravaginal and localized systems offer promising solutions for site-specific therapy with minimal systemic toxicity.

Despite substantial progress, challenges such as scalability, regulatory approval, long-term safety, and cost-effectiveness must be addressed before widespread clinical adoption. Future research should emphasize well-designed clinical trials, personalized nanomedicine approaches, and integration with immunotherapy and gene therapy. Overall, novel drug delivery systems are poised to play a crucial role in improving clinical outcomes and quality of life for patients with cervical cancer.

**REFERENCES**


1. Peer D, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2020;15:751–760.
2. Torchilin VP. Multifunctional nanocarriers for drug delivery. Adv Drug Deliv Rev. 2021;173:1–21.
3. Jain NK, Mishra V. Recent advances in nanotechnology-based drug delivery systems for cancer therapy. Drug Deliv Transl Res. 2022;12:1234–1250.
4. Zhang Y, et al. Targeted nanomedicine strategies for gynecological cancers. Front Pharmacol. 2024;15:1189–1205.
5. Vikram, S. INTELLIGENT SYSTEMS AND APPLICATIONS IN ENGINEERING.
6. Bhagwat, V. B. (2025). Simplifying Payroll Balance Conversions in Payroll Systems Implementation through the Use of Generative AI.
7. Rongali, L. P. (2022). Fostering Collaboration and Shared Ownership in Globally Distributed DevOps Teams: Challenges and Best Practices. European Journal of Advances in Engineering and Technology, 9(6), 96-102.
8. Tiwary AK, et al. Solid lipid nanoparticles for targeted cervical cancer therapy. Pharm Res. 2025;42:455–472.
9. Mahesh Ganji. (2025). Enhancing Oracle Cloud HR Reporting Through AI-Driven Automation. Journal of Science & Technology, 10(6), 28–36. https://doi.org/10.46243/jst.2025.v10.i06.pp28-36
10. Mallick, P. (2025). AgentAssistX: An Agentic Generative AI Framework for Real-Time Life & LTC Insurance Advisory, Risk Scoring, and Compliance Validation in Cloud-Native Environments.
11. Peer, Dan, et al. 2020. “Nanocarriers as an Emerging Platform for Cancer Therapy.” Nature Nanotechnology 15: 751–760.
12. Torchilin, Vladimir P. 2021. “Multifunctional Nanocarriers for Drug Delivery.” Advanced Drug Delivery Reviews 173: 1–21.
13. Naga Charan, N. (2022). Predictive Sql Injection Detection And Prevention Using Machine Learning Across Aws, Azure, And Google Cloud Platforms. International Journal of Engineering Science and Advanced Technology, 22(8), 68–74. https://doi.org/10.64771/ijesat.2022.v22.i08.pp68-74
14. Todupunuri, A. (2024). Exploring the use of generative AI in creating deepfake content and the risks it poses to data integrity, digital identities, and security systems. Available at SSRN 5014688.
15. Jain, N. K., and V. Mishra. 2022. “Recent Advances in Nanotechnology-Based Drug Delivery Systems for Cancer Therapy.” Drug Delivery and Translational Research 12: 1234–1250.
16. Zhang, Y., et al. 2024. “Targeted Nanomedicine Strategies for Gynecological Cancers.” Frontiers in Pharmacology 15: 1189–1205.

17. Tiwary, A. K., et al. 2025. “Solid Lipid Nanoparticles for Targeted Cervical Cancer Therapy: Recent Advances and Future Prospects.” Pharmaceutical Research 42: 455–472.